Self-reported side effects in buprenorphine and methadone patients receiving antiretroviral therapy: Results from the MANIF 2000 cohort study

Addiction

Volumn 105, Issue 12, 2010, Pages 2160-2168

  Patrizia Carrieri, Patrizia ^a,b,c   Roux, Perrine ^a,b,c   Cohen, Julien ^a,b,c   Ravaux, Isabelle ^d   Dellamonica, Pierre ^e   Protopopescu, Camelia ^a,b,c   Spire, Bruno ^a,b,c   Rosenblum, Andrew ^f  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

Author keywords

HAART; Opioid agonist treatment; Pain; Selection models; Side effects

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE; METHADONE;

ARTICLE; ATTITUDE TO HEALTH; COHORT ANALYSIS; DEPRESSION; FEMALE; FRANCE; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PAIN; PATIENT COMPLIANCE; SELF REPORT; SUBSTANCE ABUSE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ANTI-RETROVIRAL AGENTS; ATTITUDE TO HEALTH; BUPRENORPHINE; COHORT STUDIES; DEPRESSION; FEMALE; FRANCE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PAIN; SELF REPORT; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 78249236576     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.03108.x     Document Type: Article

References (43)

1. Ammassari A., Murri R., Pezzotti P., Trotta M. P., Ravasio L., De Longis P. et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28: 445-9.
2. Carrieri M. P., Chesney M. A., Spire B., Loundou A., Sobel A., Lepeu G. et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med 2003; 10: 1-14.
3. Bassetti S., Battegay M., Furrer H., Rickenbach M., Flepp M., Kaiser L. et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 1999; 21: 114-9.
4. Clarke S., Delamere S., McCullough L., Hopkins S., Bergin C., Mulcahy F. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Med 2003; 4: 33-7.
5. O'Brien M. E., Clark R. A., Besch C. L., Myers L., Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34: 407-14.
6. Kerr T., Marshall A., Walsh J., Palepu A., Tyndall M., Montaner J. et al. Determinants of HAART discontinuation among injection drug users. AIDS Care 2005; 17: 539-49.
7. Roux P., Carrieri M. P., Villes V., Dellamonica P., Poizot-Martin I., Ravaux I. et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008; 103: 1828-36.
8. Roux P., Carrieri M. P., Cohen J., Ravaux I., Poizot-Martin I., Dellamonica P. et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis 2009; 49: 1433-40.
9. Lucas G. M., Weidle P. J., Hader S., Moore R. D. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis 2004; 38: Suppl 5:S409-13.
10. Bouhnik A. D., Carrieri M. P., Rey D., Spire B., Gastaut J. A., Gallais H. et al. Drug injection cessation among HIV-infected injecting drug users. Addict Behav 2004; 29: 1189-97.
11. Carrieri M. P., Vlahov D., Dellamonica P., Gallais H., Lepeu G., Spire B. et al. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug Alcohol Depend 2000; 60: 51-4.
12. Michel L., Roux P., Cohen J., Carrieri M. P. A French prospective observational study of the treatment of chronic hepatitis C in drug abusers: a commentary. Gastroenterol Clin Biol 2009; 33: 15-16; author reply 6-7.
13. Carrieri M. P., Amass L., Lucas G. M., Vlahov D., Wodak A., Woody G. E. Buprenorphine use: the international experience. Clin Infect Dis 2006; 43: Suppl 4:S197-215.
14. Carrieri M. P., Villes V., Raffi F., Protopopescu C., Preau M., Salmon D. et al. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). Int J Drug Policy 2007; 18: 288-95.
15. Rosenblum A., Joseph H., Fong C., Kipnis S., Cleland C., Portenoy R. K. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003; 289: 2370-8.
16. Hay J. L., White J. M., Bochner F., Somogyi A. A., Semple T. J., Rounsefell B. Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. J Pain 2009; 10: 316-22.
17. Duran S., Solas C., Spire B., Carrieri M. P., Fuzibet J. G., Costagliola D. et al. 'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS 2001; 15: 1075-7.
18. Justice A. C., Holmes W., Gifford A. L., Rabeneck L., Zackin R., Sinclair G. et al. Development and validation of aself-completed HIV symptom index. J Clin Epidemiol 2001; 54: Suppl 1:S77-90.
19. Bissell D., Paton A., Ritson B. ABC of alcohol. Help: referral. BMJ (Clin Res Edn) 1982; 284: 495-7.
20. Messiah A., Loundou A. D., Maslin V., Lacarelle B., Moatti J. P. Physician recognition of active drug use in HIV-infected patients is lower than validity of patient's self-reported drug use. J Pain Symptom Manage 2001; 21: 103-12.
21. Fuhrer R., Rouillon F., Lellouch J. Diagnostic reliability among French psychiatrists using DSM-III criteria. Acta Psychiatr Scand 1986; 73: 12-6.
22. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 3: 385-491.
23. Zastrow A., Faude V., Seyboth F., Niehoff D., Herzog W., Lowe B. Risk factors of symptom underestimation by physicians. J Psychosom Res 2008; 64: 543-51.
24. Shelton B. J., Gilbert G. H., Lu Z., Bradshaw P., Chavers L. S., Howard G. Comparing longitudinal binary outcomes in an observational oral health study. Stat Med 2003; 22: 2057-70.
25. Mathews W. C., McCutchan J. A., Asch S., Turner B. J., Gifford A. L., Kuromiya K. et al. National estimates of HIV-related symptom prevalence from the HIV Cost and Services Utilization Study. Med Care 2000; 38: 750-62.
26. Vaccarino A. L., Sills T. L., Evans K. R., Kalali A. H. Prevalence and association of somatic symptoms in patients with major depressive disorder. J Affect Disord 2008; 110: 270-6.
27. Preau M., Protopopescu C., Spire B., Sobel A., Dellamonica P., Moatti J. P. et al. Health related quality of life among both current and former injection drug users who are HIV-infected. Drug Alcohol Depend 2007; 86: 175-82.
28. Tsao J. C., Stein J. A., Dobalian A. Pain, problem drug use history, and aberrant analgesic use behaviors in persons living with HIV. Pain 2007; 133: 128-37.
29. Carrieri M. P., Moatti J. P., Vlahov D., Obadia Y., Reynaud-Maurupt C., Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Commun Health 1999; 53: 4-8.
30. Mattick R. P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008 (issue 2); CD002207.
31. Alford D. P., LaBelle C. T., Richardson J. M., O'Connell J. J., Hohl C. A., Cheng D. M. et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med 2007; 22: 171-6.
32. Fishman S. M., Wilsey B., Mahajan G., Molina P. Methadone reincarnated: novel clinical applications with related concerns. Pain Med 2002; 3: 339-48.
33. Johnson R. E., Fudala P. J., Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005; 29: 297-326.
34. Silverberg M. J., Jacobson L. P., French A. L., Witt M. D., Gange S. J. Age and racial/ethnic differences in the prevalence of reported symptoms in human immunodeficiency virus-infected persons on antiretroviral therapy. J Pain Symptom Manage 2009; 38: 197-207.
35. Carr A., Amin J. Efficacy and tolerability of initial antiretroviral therapy: a systematic review. AIDS 2009; 23: 343-53; discussion 55-6.
36. Kilbourne A. M., Justice A. C., Rabeneck L., Rodriguez-Barradas M., Weissman S. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol 2001; 54: Suppl 1:S22-8.
37. Conner K. R., Pinquart M., Duberstein P. R. Meta-analysis of depression and substance use and impairment among intravenous drug users (IDUs). Addiction 2008; 103: 524-34.
38. Walkup J., Wei W., Sambamoorthi U., Crystal S. Antidepressant treatment and adherence to combination antiretroviral therapy among patients with AIDS and diagnosed depression. Psychiatr Q 2008; 79: 43-53.
39. Joe G. W., Simpson D. D., Broome K. M. Retention and patient engagement models for different treatment modalities in DATOS. Drug Alcohol Depend 1999; 57: 113-25.
40. Woolridge E., Barton S., Samuel J., Osorio J., Dougherty A., Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 2005; 29: 358-67.
41. Magura S., Goldsmith D., Casriel C., Goldstein P. J., Lipton D. S. The validity of methadone clients' self-reported drug use. Int J Addict 1987; 22: 727-49.
42. Breitbart W., Rosenfeld B., Passik S., Kaim M., Funesti-Esch J., Stein K. A comparison of pain report and adequacy of analgesic therapy in ambulatory AIDS patients with and without a history of substance abuse. Pain 1997; 72: 235-43.
43. Touloumi G., Babiker A. G., Pocock S. J., Darbyshire J. H. Impact of missing data due to drop-outs on estimators for rates of change in longitudinal studies: a simulation study. Stat Med 2001; 20: 3715-28.